This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Play TheStreet's FDA Drug-Approval Contest

Stocks in this article: VVUS CTIC CORT DSCO CRIS MAPP CHTP

BOSTON ( TheStreet) -- Welcome to TheStreet's 2012 FDA Drug Approval Prediction Contest.

Your challenge: Correctly pick the approval decisions to be made by the U.S. Food and Drug Administration on 17 drugs between January and April. The person(s) with the most accurate predictions will receive a hearty congratulations, a mention in a future column and bragging rights as the best FDA drug-approval prognosticator of 2012.

I organized a similar FDA drug-approval contest in October 2010. Three winners emerged among 94 contestants, each correctly predicting 10 of 11 FDA decisions over the course of one month. This year's contest presents a tougher challenge -- more FDA drug-approval decisions spread out over four months.

You have three outcomes to choose from for each drug-approval decision:

1. Full Approval: The big win, meaning the drug is approved and can be marketed for sale immediately.

2. Complete Response Letter: The FDA has some concerns or issues (incomplete data, labeling, risk management, etc.) that prevent the drug from being approved immediately. In other words, the drug's approval is rejected or delayed for some reason.

3. No Decision: The FDA chooses to extend the drug's review time, i.e., pushes out the approval decision to a later date.

The 17 drugs up for FDA approval are listed below in chronological order. Use one of three choices for your prediction: Full Approval, Complete Response Letter or No Decision.

To play TheStreet's FDA Drug Approval Prediction Contest, please copy the drug list, write in your approval prediction, and post your predictions using the "Add Comment" button found at the top or bottom of this Web page. You'll need to complete a short registration to post a comment -- make sure you include a valid email address so we can contact the winners.

Please post your picks by Thursday, Jan. 26, at midnight. Entries received after the deadline are still eligible for the contest, but you won't get credit for drug-approval decisions already made by the time your entry was received.

Good luck!

Pending FDA Drug Approval Decisions:

Jan. 27: Amylin Pharmaceuticals' (AMLN) Bydureon for diabetes.
Feb. 14: BioSante Pharmaceuticals' (BPAX) Bio-T-Gel for hypogonadism.
Feb. 17: Corcept Therapeutics' (CORT) Corlux for Cushing's sydrome.
Feb. 26: Columbia Labs' (CBRX) Prochieve for reduction of risk of preterm birth.
March 6: Discovery Labs' (DSCO) Surfaxin for respiratory distress syndrome.
March 6: Astex Pharmaceuticals' (ASTX) Dacogen for acute myeloid leukemia.
March 7: Neurogesx' (NGSX) Qutenza for HIV-related nerve pain.
March 8: Roche and Curis' (CRIS) vismodegib for basal cell carcinoma.
March 26: MAP Pharmaceuticals' (MAPP) Levadex for migraines.
March 27: Affymax's (AFFY) peginesatide for anemia due to chronic kidney disease.
March 28: Chelsea Therapeutics' (CHTP) Northera for orthostatic hypotension.
April 17: Vivus' (VVUS) Qnexa for obesity.
April 18: Vertex Pharmaceuticals' (VRTX) Kalydeco for cystic fibrosis
April 24: Cell Therapeutics' (CTIC) pixantrone for non-Hodgkin's lymphoma
April 26: Amgen's (AMGN) Xgeva for prevention or delay of spread of prostate cancer to bone.
April 27: Vivus' (VVUS) avanafil for erectile dysfunction.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:

Follow TheStreet on Twitter and become a fan on Facebook.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,778.15 +421.28 2.43%
S&P 500 2,061.23 +48.34 2.40%
NASDAQ 4,748.3960 +104.0840 2.24%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs